MindBio Therapeutics Corp., a biotechnology company developing artificial intelligence-driven voice analytics for drug and alcohol intoxication detection, has completed manufacturing of its next-generation Edge AI Intoxication Detection Kiosk. The hardware builds on a prototype developed in June and is designed to support the company's proprietary Voice AI technology, which analyzes vocal characteristics to identify potential impairment.
The completion of manufacturing marks a critical step toward commercial deployment. MindBio is now continuing software integration, system testing, and validation of its predictive models against conventional breath alcohol and oral fluid testing methods. A potential initial commercial pilot is targeted for later this year, which would provide an opportunity to evaluate the technology's performance in a real-world environment against existing testing methods.
The kiosk is being developed as a rapid, non-invasive alternative to conventional drug and alcohol screening. It targets safety-sensitive industries including mining, aviation, construction, heavy transport, and law enforcement. By enabling more frequent, large-scale workplace screening, MindBio aims to potentially reduce testing costs, administration time, and operational disruptions. The company's AI prediction model uses over 50 million data points to predict alcohol intoxication with remarkable accuracy, just by using the human voice. This approach could allow employers to conduct more comprehensive screening without the logistical hurdles of traditional methods.
For investors, the announcement signals progress toward commercialization in a niche where demand is driven by regulatory requirements and workplace safety concerns. The planned pilot will be a key validation milestone, as it will test the technology's accuracy and reliability in real-world conditions. If successful, MindBio could position itself as a disruptive player in the estimated multi-billion-dollar drug and alcohol testing market.
MindBio Therapeutics (CSE: MBIO; Frankfurt: WF6; OTCQB: MBQIF) is commercialising AI prediction technologies for drug and alcohol intoxication detection via voice analysis. The company is developing an enterprise platform including Edge-AI kiosks integrating bespoke hardware and software for detection in a range of enterprise environments including the mining industry, aviation, construction, and law enforcement.
To view the full press release, visit https://ibn.fm/UN9LN. The latest news and updates relating to MBQIF are available in the company's newsroom at https://ibn.fm/MBQIF.
The announcement was disseminated through TechMediaWire, a specialized communications platform focused on pioneering public and private companies driving the future of technology. TechMediaWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN that delivers access to a vast network of wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and a full array of tailored corporate communications solutions.
Please see full terms of use and disclaimers on the TechMediaWire website applicable to all content provided by TMW, wherever published or re-published: https://www.TechMediaWire.com/Disclaimer.
